$BPTH,,,Another stock I keep on my radar,,,finished the day yesterday @ $.39 and up $.03 in After Hours right now. This stock has been consolidating and trading at the $.40 level since June 1st. All of the indicators I look at are heading in the positive direction. As with the other stocks I have mentioned, this needs to see some volume as yesterday was below the average daily volume. I will see how this shakes out this morning.
Following explains where this company currently presently looks:
Bio-Path Holdings (BPTH) Is At $0.43
Bio-Path Holdings Inc (BPTH) formed wedge down with $0.41 target or 5.00% below today’s $0.43 share price. Bio-Path Holdings Inc (BPTH) has $38.22 million valuation. About shares traded. Bio-Path Holdings Inc (NASDAQ:BPTH) has declined 82.37% since July 19, 2016 and is downtrending. It has underperformed by 99.07% the S&P500.
Investors sentiment increased to 1.93 in 2016 Q4. Its up 0.01, from 1.92 in 2016Q3. It increased, as 5 investors sold Bio-Path Holdings Inc shares while 9 reduced holdings. 9 funds opened positions while 18 raised stakes. 19.14 million shares or 4.05% less from 19.95 million shares in 2016Q3 were reported. Geode Cap Management Limited Company owns 682,477 shares. Credit Suisse Ag invested 0% of its portfolio in Bio-Path Holdings Inc (NASDAQ:BPTH). Blackrock Advsr Ltd Limited Liability Company reported 49,387 shares. Voya Investment Mngmt Ltd holds 44,232 shares. Proshare Ltd Limited Liability Company reported 0% stake. Amalgamated Comml Bank reported 10,845 shares or 0% of all its holdings. Schwab Charles Investment Inc has 0% invested in Bio-Path Holdings Inc (NASDAQ:BPTH) for 131,200 shares. Rhumbline Advisers reported 0% of its portfolio in Bio-Path Holdings Inc (NASDAQ:BPTH). Tiaa Cref Management reported 0% in Bio-Path Holdings Inc (NASDAQ:BPTH). Jpmorgan Chase holds 0% or 120,669 shares. Kcg Hldg Incorporated reported 0% in Bio-Path Holdings Inc (NASDAQ:BPTH). Moreover, Morgan Stanley has 0% invested in Bio-Path Holdings Inc (NASDAQ:BPTH) for 257,550 shares. Barclays Public Ltd Liability Com accumulated 1,662 shares or 0% of the stock. Vanguard Grp Incorporated has 2.90 million shares for 0% of their portfolio. American Grp invested in 0% or 47,756 shares.
Analysts await Bio-Path Holdings Inc (NASDAQ:BPTH) to report earnings on August, 8. They expect $-0.02 earnings per share, 0.00% or $0.00 from last year’s $-0.02 per share. After $-0.01 actual earnings per share reported by Bio-Path Holdings Inc for the previous quarter, Wall Street now forecasts 100.00% negative EPS growth.
BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.
Following explains where this company currently presently looks:
Bio-Path Holdings (BPTH) Is At $0.43
Bio-Path Holdings Inc (BPTH) formed wedge down with $0.41 target or 5.00% below today’s $0.43 share price. Bio-Path Holdings Inc (BPTH) has $38.22 million valuation. About shares traded. Bio-Path Holdings Inc (NASDAQ:BPTH) has declined 82.37% since July 19, 2016 and is downtrending. It has underperformed by 99.07% the S&P500.
Investors sentiment increased to 1.93 in 2016 Q4. Its up 0.01, from 1.92 in 2016Q3. It increased, as 5 investors sold Bio-Path Holdings Inc shares while 9 reduced holdings. 9 funds opened positions while 18 raised stakes. 19.14 million shares or 4.05% less from 19.95 million shares in 2016Q3 were reported. Geode Cap Management Limited Company owns 682,477 shares. Credit Suisse Ag invested 0% of its portfolio in Bio-Path Holdings Inc (NASDAQ:BPTH). Blackrock Advsr Ltd Limited Liability Company reported 49,387 shares. Voya Investment Mngmt Ltd holds 44,232 shares. Proshare Ltd Limited Liability Company reported 0% stake. Amalgamated Comml Bank reported 10,845 shares or 0% of all its holdings. Schwab Charles Investment Inc has 0% invested in Bio-Path Holdings Inc (NASDAQ:BPTH) for 131,200 shares. Rhumbline Advisers reported 0% of its portfolio in Bio-Path Holdings Inc (NASDAQ:BPTH). Tiaa Cref Management reported 0% in Bio-Path Holdings Inc (NASDAQ:BPTH). Jpmorgan Chase holds 0% or 120,669 shares. Kcg Hldg Incorporated reported 0% in Bio-Path Holdings Inc (NASDAQ:BPTH). Moreover, Morgan Stanley has 0% invested in Bio-Path Holdings Inc (NASDAQ:BPTH) for 257,550 shares. Barclays Public Ltd Liability Com accumulated 1,662 shares or 0% of the stock. Vanguard Grp Incorporated has 2.90 million shares for 0% of their portfolio. American Grp invested in 0% or 47,756 shares.
Analysts await Bio-Path Holdings Inc (NASDAQ:BPTH) to report earnings on August, 8. They expect $-0.02 earnings per share, 0.00% or $0.00 from last year’s $-0.02 per share. After $-0.01 actual earnings per share reported by Bio-Path Holdings Inc for the previous quarter, Wall Street now forecasts 100.00% negative EPS growth.
BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
